Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
KEYNOTE-240 trial: what clinicians have said so far
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
- NCT02702401 ↗
- Completed
- Merck Sharp & Dohme LLC
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on KEYNOTE-240 (pembrolizumab in previously systemically treated advanced hepatocellular carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-240 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 24 posts on X, typically up to 106 once built | |
| 4 podcast episodes, typically up to 18 once built | |
| 2 YouTube videos, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Pembrolizumab; Placebo; Best Supportive Care
- Arms
- Pembrolizumab+Best Supportive Care · Experimental
- Placebo+Best Supportive Care · Placebo comparator
- Enrollment
- 413
- Primary outcomes
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- May 26, 2016
- Primary completion
- Jan 2, 2019
- Results posted
- Yes
- Registry record
- NCT02702401 · updated Sep 29, 2022
Publications
linked from the registry- Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2. PubMed 31790344
- Chan SL, Finn RS, Edeline J, Ogasawara S, Knox JJ, Daniele B, Ryoo BY, Merle P, Bouattour M, Lim HY, Chao Y, Yau T, Haber BA, Malhotra U, Siegel AB, Liu CC, Kudo M, Cheng AL. Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma. Ann Hepatol. 2026 Jan-Jun;31(1):102169. doi: 10.1016/j.aohep.2025.102169. Epub 2025 Dec 24. PubMed 41453647
- Finn RS, Gu K, Chen X, Merle P, Lee KH, Bouattour M, Cao P, Wang W, Cheng AL, Zhu L, Lim HY, Kudo M, Pan Y, Chang TT, Edeline J, Li W, Yang P, Li C, Li J, Siegel AB, Qin S. Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies. JHEP Rep. 2025 Feb 4;7(6):101350. doi: 10.1016/j.jhepr.2025.101350. eCollection 2025 Jun. PubMed 40486134
- Vogel A, Merle P, Verslype C, Finn RS, Zhu AX, Cheng AL, Chan SL, Yau T, Ryoo BY, Knox J, Daniele B, Qin S, Wei Z, Miteva Y, Malhotra U, Siegel AB, Kudo M. ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Ther Adv Med Oncol. 2021 Sep 30;13:17588359211039928. doi: 10.1177/17588359211039928. eCollection 2021. PubMed 34616489